Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
REMINET trial (lanreotide): what clinicians have said so far
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
- NCT02288377 ↗
- Terminated
- Federation Francophone de Cancerologie Digestive
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on REMINET (lanreotide in non-resectable duodeno-pancreatic neuroendocrine tumors after first-line treatment) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REMINET so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
- Phase
- Phase 2/Phase 3
- Status
- Terminated
- Conditions
- Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
- Interventions
- lanreotide; Placebo
- Arms
- lanreotide · Experimental
- placebo · Placebo comparator
- Enrollment
- 53
- Primary outcomes
- Proportion of Patients Alive and Progression-free at 6 Months
- Sponsor
- Federation Francophone de Cancerologie Digestive
- Start
- Jan 2015
- Primary completion
- Jan 2020
- Results posted
- Yes
- Registry record
- NCT02288377 · updated Jan 18, 2023
Publications
linked from the registry- Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11. PubMed 28292641
- Guiney DG Jr, Hasegawa P, Davis CE. Homology between clindamycin resistance plasmids in Bacteroides. Plasmid. 1984 May;11(3):268-71. doi: 10.1016/0147-619x(84)90035-0. PubMed 6087395
- Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study. Eur J Cancer. 2022 Nov;175:31-40. doi: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7. PubMed 36087395